Tiny trial tracks experimental drug ABBV-932 in 8 healthy men
NCT ID NCT06953934
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This Phase 1 study will give a single dose of ABBV-932 (with a tiny radioactive marker) to 8 healthy men. The goal is to measure how the drug moves through the body, how long it stays, and how it is eliminated. Researchers will also check for any side effects. This is a safety and drug-processing study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABBV-932 (a drug being tested, given as an oral capsule with a radioactive tracer to track it)
- What could go wrong
- This is a very early, small study in just 8 healthy volunteers. It is designed to measure how the drug behaves in the body, not to treat any disease. There is no guarantee the drug will ever be tested in patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON Clinical Research /ID# 270490
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?